ARGX

argenx SE

Phase 2 AI-extracted

empasiprubart

generalized myasthenia gravis (gMG)

Resolved

7days ago

Phase 2 readout · Jun 30, 2026

What's at stake Phase 2 trial results for empasiprubart in generalized myasthenia gravis (gMG) are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 12h ago

“ADAPT-Forward combination study ongoing to evaluate empasiprubart as an add on therapy to efgartigimod in gMG”

Add to calendar Post on X Reddit

Provenance